Background. Hemolytic uremic syndrome (HUS) may present atypically without the full triad
of classical HUS. Eculizumab has been shown to be efficacious in complement-mediated …

Shiga toxin–producing Escherichia coli hemolytic uremic syndrome (STEC-HUS) is the most
common cause of acute renal failure in children, and it is associated with thrombocytopenia …

Complement activation plays an important role in the pathogenesis of atypical hemolytic
uremic syndrome. Eculizumab is a monoclonal antibody that blocks complement activity and …

Hemolytic Uremic Syndrome (HUS) is a constellation of microangiopathic hemolytic anemia,
thrombocytopenia, and acute renal failure. Shiga toxin‐producing Escherichia coli‐(STEC‐) …

Background Infection-associated hemolytic uremic syndrome (IA-HUS), most often due to
infection with Shiga toxin-producing bacteria, mainly affects young children. It can be acutely …

Haemolytic uraemic syndrome (HUS) remains a leading cause of paediatric acute kidney
injury (AKI). Haemolytic uraemic syndrome is characterised by the triad of microangiopathic …

Hemolytic uremic syndrome (HUS) is often encountered in children with acute kidney injury.
Besides the well-known shiga toxin-producing Escherichia coli-associated HUS, atypical …

Background In contrast to atypical haemolytic uraemic syndrome (aHUS), only single case
reports and limited data have been published on systemic activation of the complement …

Hemolytic uremic syndrome caused by Shiga toxin-producing E. coli (STEC-HUS) is often
associated with a severe morbidity including neurological involvement and a mortality of 1 …

The kidney and brain are the two target organs in patients with Shiga toxin-producing
Escherichia coli-associated hemolytic–uremic syndrome (STEC-HUS). Activation of the …